SCHEMBL19970535

SCHEMBL19970535

O=C(O)C1=CC2(CCC1S(=O)(=O)Cc1ccc(F)cc1Cl)O[C@@H](CO)[C@H](CO)O2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.37
CYP2D6 P10635 2/20 0.36
CYP2C19 P33261 2/20 0.36
PKM P14618 1/20 0.36
KMT2A Q03164 3/20 0.35
MEN1 O00255 2/20 0.35
HSD11B1 P28845 1/20 0.34
PSEN1 P49768 3/20 0.33
PSEN2 P49810 3/20 0.33
APH1B Q8WW43 3/20 0.33
NCSTN Q92542 3/20 0.33
APH1A Q96BI3 3/20 0.33
PSENEN Q9NZ42 3/20 0.33
EPHX2 P34913 1/20 0.33
SLC5A1 P13866 1/20 0.33
SLC5A2 P31639 1/20 0.33
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
P2RX7 Q99572 4/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19970497 1.00 ALDH1A1 (0.37) ALDH1A1GAACYP2D6CYP2C19PKM
SCHEMBL19970487 0.93 PSEN1 (0.33) ALDH1A1GAACYP2D6CYP2C19PKM
SCHEMBL19970499 0.90 KMT2A (0.37) ALDH1A1GAACYP2D6CYP2C19PKM
SCHEMBL19970495 0.89 CYP2D6 (0.34) ALDH1A1GAACYP2D6CYP2C19PKM
SCHEMBL19970505 0.89 P2RX7 (0.31) P2RX7
SCHEMBL14216749 0.88 TLR4 (0.44) ALDH1A1GAACYP2D6CYP2C19PKM
SCHEMBL20111169 0.88 TLR4 (0.44) ALDH1A1GAACYP2D6CYP2C19PKM
SCHEMBL19970494 0.88 ALDH1A1 (0.34) ALDH1A1GAACYP2D6CYP2C19PKM
SCHEMBL19970509 0.87 ALDH1A1 (0.35) ALDH1A1GAACYP2D6CYP2C19PKM
SCHEMBL19970533 0.86 LMNA (0.36) ALDH1A1GAACYP2C19KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180118708-A1 CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-03 US claimed
EP-3296296-A1 CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2018-03-21 EP claimed
US-20180118708-A1 CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-05-03 US disclosed
EP-3296296-A1 CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118708-A1 CYCLIC COMPOUND TLR4, TLR3, TLR9 ALDH1A1 973/4885GAA 4730/4885CYP2D6 3591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.